A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors
Matthew H. Kulke(Moffitt Cancer Center), Charles S. Fuchs(University of Southern California), Pankaj Bhargava(University of North Carolina at Chapel Hill), Keith Stuart(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), C. Lawrence(Beth Israel Deaconess Medical Center), Craig C. Earle(Canadian Partnership Against Cancer), M. Attawia(Johnson & Johnson (United States)), J. A. Meyerhardt(Beth Israel Deaconess Medical Center)
Cited by 92
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k